SEOUL, Korea--(BUSINESS WIRE)--The Korea-based international pharmaceutical company, SK Biopharmaceuticals, announced that they entered into a co-development agreement with SK Chemicals for its novel new small molecule YKP10811 that is being developed for the treatment of irritable bowel syndrome with constipation (IBS-C). Both companies are part of the SK Group, the third largest conglomerate in Korea. SK Chemicals established itself as a leading pharmaceuticals franchise for the treatment of gastrointestinal diseases that includes such important products as Levopride®, to control gastrointestinal tract movement, and Omed®, a new formulation for gastritis.
